What does Clene do?
Clene Inc. is a clinical-stage biopharmaceutical company focused on nanomedicine for neurodegenerative disease. Its central proposition is that impaired cellular energy production and oxidative stress are not merely consequences of diseases such as amyotrophic lateral sclerosis, multiple sclerosis, and Parkinson’s disease; they are potentially actionable biological drivers. Clene’s lead candidate, CNM-Au8, is an oral suspension of catalytically active, clean-surfaced gold nanocrystals designed to support mitochondrial function, improve the cell’s nicotinamide adenine dinucleotide balance, and reduce damaging reactive oxygen species.
The company trades on the Nasdaq Capital Market under CLNN and reports as a pharmaceutical-preparations issuer. It is headquartered in Salt Lake City, with research and manufacturing operations in Maryland. Clene’s official CNM-Au8 overview says the program has accumulated more than 1,000 patient-years of exposure without an identified safety signal. That safety record matters because a chronic neurodegenerative therapy must be taken for long periods, yet safety alone does not establish efficacy or regulatory approval.
How is the company organized?
Clene reports one Products segment, operates an integrated development and manufacturing model, and remains economically dependent on clinical milestones and external capital. The three neurological indications share a platform but have different endpoints, timelines, and commercial risks.
How does Clene make money when drug revenue is still absent?
Clene does not yet earn meaningful revenue from an approved medicine. Its reported sales come mainly from small dietary-supplement product and royalty arrangements, while the company’s research program is funded through equity issuance, borrowings, grants, and refundable research-and-development credits. This distinction is fundamental: current revenue does not validate the economics of CNM-Au8 and cannot support the company’s operating cost base.
Which revenue streams exist today?
| Stream | FY2025 amount | Economic interpretation |
|---|---|---|
| Product revenue | $119,000 | Sales of dietary-supplement products; not pharmaceutical revenue. |
| Royalty revenue | $81,000 | Royalties under legacy commercial arrangements. |
| Total revenue | $200,000 | Economically immaterial beside FY2025 operating expenses of $23.3 million. |
| Development funding | Equity, debt, grants, and R&D credits | The real financing engine until a drug reaches the market or a partner funds development. |
The 2025 Form 10-K reported that $198,000 of the year’s $200,000 revenue related to agreements with 4Life, a related party. By contrast, Clene had accumulated financing since inception through December 31, 2025 of approximately $195.7 million from equity sales, $71.1 million from borrowings, $15.8 million from grants, $10.1 million from refundable R&D credits, $9.4 million from its reverse recapitalization, and $1.1 million from option and warrant exercises. The 2025 Form 10-K therefore presents a company financed by capital markets and non-dilutive support, not by customer cash flow.
Which clinical assets and evidence matter most?
CNM-Au8 is the value center. Clene’s official pipeline places ALS closest to regulation, with multiple sclerosis and Parkinson’s disease providing platform optionality. Success in ALS could validate the platform; failure would weaken financing leverage and confidence in the broader thesis.
What does the ALS evidence actually show?
| Evidence source | Reported result | Research interpretation |
|---|---|---|
| RESCUE-ALS Phase 2 | 45 participants; 36-week randomized period; 30 mg CNM-Au8 versus placebo | Controlled evidence, but from a small sample. |
| HEALEY ALS Platform Trial and extension | Long-term analysis reported a 60% lower mortality risk versus matched PRO-ACT controls; hazard ratio 0.431 | Potential survival signal, but external controls are less definitive than a confirmatory trial. |
| March 2025 cross-regimen analysis | Median survival of 951 days versus 753 days, a 198-day difference; restricted mean survival time improved by 124 days | Supports consistency across datasets, subject to matching methodology. |
| RESTORE-like subgroup analysis | Median survival of 1,079 days versus 628 days; 49% mortality-risk reduction; 215-day restricted mean survival gain | Supports the confirmatory population, with subgroup limitations. |
| NIH ACT-EAP matched analysis | Week-36 neurofilament-light area-under-curve result p=0.0373; geometric mean ratio 0.914 | Relevant to accelerated approval if FDA accepts NfL and the total package. |
In May 2026, Clene reported that minutes from a Type C meeting indicated its proposed data package “may be capable” of supporting an NDA submission and review under accelerated approval, with neurofilament light potentially serving as a surrogate endpoint. The wording is conditional, not an approval commitment. The company’s May 2026 FDA meeting update also described RESTORE-ALS as the planned post-approval confirmatory study, targeted to begin in the first quarter of 2027.
What does Clene’s latest quarter show?
The quarter ended March 31, 2026 shows lower reported operating costs but a heavier financing burden. Revenue remained negligible and operating loss narrowed, while net loss widened because of equity, warrant, and derivative charges.
Why did operating expense fall so sharply?
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Revenue | $15,000 | $81,000 | No commercial drug contribution. |
| R&D expense | $329,000 | $1.5M | Reported expense was reduced by approximately $4.1M of grant funding; the low net figure understates underlying activity. |
| G&A expense | $1.7M | $2.7M | Lower personnel and professional costs contributed to the decline. |
| Operating loss | $2.1M | $4.1M | A better operating result, but not a sustainable profitability signal. |
| Net loss | $8.1M | $0.8M | Q1 2026 included $4.6M of initial-equity-issuance loss, $0.4M of warrant issuance cost, and other fair-value movements. |
| Operating cash use | $4.5M | $5.0M | Cash burn improved by about $0.5M year over year but remained substantial relative to cash on hand. |
The Q1 2026 Form 10-Q reported a $0.69 loss per share on 11.6 million weighted-average shares, versus $0.09 on 8.0 million a year earlier. The expanding denominator shows how financing can dilute per-share outcomes even when enterprise value improves.
How did Clene reach its current regulatory inflection point?
Clene’s history is a sequence of scientific, financing, and regulatory decisions that produced a near-term NDA opportunity alongside substantial evidence and liquidity risk.
-
2013Robert Etherington became president and chief executive officer. The long tenure created continuity around the nanocrystal platform.
-
2019The HEALEY ALS Platform Trial selected CNM-Au8 as one of its initial regimens, connecting Clene to an ALS trial infrastructure of more than 50 clinics.
-
2020The reverse recapitalization and Nasdaq listing expanded access to public capital, which became essential for sustaining clinical development.
-
2021–2022RESCUE-ALS and HEALEY generated randomized Phase 2 data and opened longer-term extensions, shifting the narrative toward survival and biomarker evidence.
-
2024The NIH-supported ACT-EAP program broadened real-world access and created an additional matched-control dataset, while grant funding reduced the company’s net research cost.
-
2025Cross-regimen survival analyses and NfL responder work strengthened a biomarker-led route without replacing confirmatory evidence.
-
2026FDA meeting minutes supported accelerated-approval filing preparation, while new equity and amended debt maturities funded the work.
What changed strategically in 2026?
The company moved from arguing that its data deserved regulatory consideration to preparing a specific submission. Management said the NDA would use HEALEY Phase 2 and open-label-extension data, RESCUE-ALS results, and ACT-EAP evidence. The planned confirmatory RESTORE-ALS study would start after the filing and, under an accelerated-approval scenario, continue after launch. This sequencing could shorten time to market, but it also transfers substantial scientific and financing risk into the post-submission period.
What gives Clene a competitive advantage—and where is the moat unproven?
Clene’s potential advantage combines mechanism, oral formulation, safety exposure, intellectual property, and proprietary manufacturing. CNM-Au8 could address bioenergetic failure across genetically diverse patients, supporting a broad ALS label if efficacy is established. Clene reported more than 160 issued patents and about five pending applications at December 31, 2025.
How durable are the company’s resources?
Which therapies define the competitive context?
| Therapy or approach | Position in ALS care | Implication for CNM-Au8 |
|---|---|---|
| Riluzole | Established oral standard with modest survival benefit | CNM-Au8 must demonstrate additive value, practical co-administration, and reimbursement justification. |
| Edaravone | Approved oxidative-stress-oriented therapy with oral and infusion formulations | Creates mechanistic and commercial comparison around function, convenience, and patient selection. |
| Tofersen | Mutation-specific therapy for SOD1-associated ALS | Shows that biomarker-linked accelerated approval is possible, while CNM-Au8 seeks a much broader population. |
| Investigational pipelines | Gene, RNA, immune, metabolic, and neuroprotective programs from better-funded developers | Clene competes for patients, investigators, regulatory attention, partners, and capital—not only eventual prescriptions. |
The moat is conditional: patents and manufacturing know-how matter only if regulators and clinicians accept the benefit. Approval could make those assets more valuable because nanocrystal process transfer may be difficult and accumulated safety exposure may reduce adoption friction.
How financially strong is Clene?
Finance is the main constraint on Clene’s science. At March 31, 2026, cash was $5.9 million, total assets $21.7 million, liabilities $40.5 million, and stockholders’ deficit $18.8 million. Accumulated deficit reached $316.4 million, and management’s plans did not alleviate going-concern doubt for the following year.
What does the balance sheet reveal?
| Balance-sheet item | March 31, 2026 | Interpretation |
|---|---|---|
| Cash | $5.9M | Roughly one quarter of recent annualized operating cash use before later financing. |
| Current assets | $13.0M | Included grant receivables and other assets, not just unrestricted cash. |
| Notes payable | $5.6M | Current and long-term carrying amounts combined. |
| Convertible notes | $12.6M | Cash and dilution exposure; maturity later extended to August 13, 2027. |
| Warrant liabilities | $12.0M | Fair-value movements can create large non-cash earnings volatility. |
| Stockholders’ deficit | $(18.8)M | Reflects cumulative financing pressure. |
How much financing flexibility remains?
Clene raised $6.0 million gross in Q1 2026 and announced another $7.0 million offering at $7.00 per share on May 6. Lenders then extended certain notes to August 13, 2027 and deferred payment. The steps improved runway but did not remove funding needs; secured convertible notes also require at least $2.0 million of unrestricted cash.
Financial strength should be judged by milestone-adjusted runway. Funds must cover NDA work, manufacturing readiness, and RESTORE-ALS without excessively dilutive financing. The annual filing also reported material weaknesses in internal control over financial reporting.
Who owns Clene stock, and why does it matter?
Clene uses one-share, one-vote common stock, but ownership is concentrated among insiders, financing affiliates, and specialist investors. Proxy percentages include securities exercisable or convertible within 60 days, so they measure potential influence rather than only current common shares.
| Holder or group | Beneficial ownership | Proxy percentage | Why it matters |
|---|---|---|---|
| All directors and executive officers as a group | 4,060,320 shares | 28.3% | Creates meaningful alignment and influence over financing, compensation, and board decisions. |
| Alison Mosca and affiliated interests | 1,946,835 shares | 14.9% | Includes affiliated entities and convertible-note exposure, linking governance to financing relationships. |
| Chidozie Ugwumba / SymBiosis II | 1,724,358 shares | 13.3% | A large biotechnology-focused holder can materially influence voting outcomes. |
| Vivo Opportunity Fund | 1,886,469 shares | 9.9% | Represents specialist institutional capital with substantial economic exposure. |
| David Matlin | 929,822 shares | 7.7% | Board-linked ownership adds direct influence over strategic and financing oversight. |
| Robert Etherington, CEO | 332,851 shares | 2.8% | Most of the position included exercisable options, aligning value creation with equity performance while increasing dilution sensitivity. |
How concentrated is beneficial ownership?
The 2026 proxy statement used 11.8 million outstanding shares at March 25, 2026 and proposed expanding the equity plan from 3.22 million to 4.22 million shares. Governance analysis therefore must include voting influence and dilution from compensation, warrants, and convertibles.
What opportunities and risks could change the story?
ALS has high unmet need, and a broadly applicable oral therapy could be meaningful. Clene estimated the global market could exceed $1.5 billion by 2032, but realized revenue would depend on label breadth, price, reimbursement, diagnosis, physician confidence, capacity, and combination use.
Which risks are most likely to affect value?
| Risk | Affected value driver | What to monitor |
|---|---|---|
| FDA rejects or delays the accelerated-approval path | Probability of approval, launch timing, and financing needs | NDA submission, filing acceptance, review designation, and requests for additional evidence. |
| NfL is not accepted as a sufficiently predictive surrogate | Regulatory probability and confirmatory-trial burden | FDA language about biomarker validation and the relationship between NfL change and clinical benefit. |
| Survival analyses do not replicate prospectively | Clinical credibility and peak penetration | RESTORE-ALS design, enrollment, event rate, and prospective mortality and function outcomes. |
| Capital is unavailable or highly dilutive | Per-share value, runway, and negotiating leverage | Cash burn, unrestricted-cash covenant, ATM activity, registered offerings, warrants, and convertible-note terms. |
| Manufacturing interruption or scale-up difficulty | Launch timing, gross margin, and supply reliability | Facility readiness, validation batches, process-transfer capability, and regulator observations. |
| Commercial adoption or reimbursement is weak | Price, penetration, and long-run cash flow | Label scope, payer coverage, treatment duration, evidence requirements, and commercial-partner strategy. |
Where could upside come from beyond ALS?
A favorable ALS decision could validate the platform and improve partnership prospects in multiple sclerosis or Parkinson’s disease. The broader pipeline should not be valued as already validated because each indication has different biology, endpoints, timelines, and reimbursement.
The official ACT-EAP program page describes evidence gathered while serving patients outside randomized trials. Such data can reinforce safety and biomarker patterns, but selection bias means it is strongest when paired with controlled evidence.
What should a DCF model and a researcher monitor next?
A steady-state DCF is poorly suited to Clene because prescription-drug revenue and normalized margins do not exist. A probability-adjusted program model should estimate CNM-Au8 cash flows by indication, weight them by approval probability, deduct corporate and trial costs, and model dilution and debt-like obligations.
Which KPIs deserve priority?
What is the key takeaway from Clene analysis?
Clene is testing a differentiated nanomedicine approach where patient need is high. Its strengths are CNM-Au8’s mechanism, safety exposure, patents, manufacturing, and an ALS package advancing toward an NDA. Its weaknesses are no approved product, negligible revenue, partly non-randomized evidence, going-concern risk, complex liabilities, and dilution.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.